Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.38
-0.22 (-3.93%)
Jan 17, 2025, 4:00 PM EST - Market closed
Coya Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coya Therapeutics stock have an average target of 16.25, with a low estimate of 14 and a high estimate of 18. The average target predicts an increase of 202.04% from the current stock price of 5.38.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 18, 2024.
Analyst Ratings
The average analyst rating for COYA stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +178.81% | Dec 18, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +178.81% | Dec 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +234.57% | Nov 11, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +160.22% | Nov 7, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +160.22% | Oct 30, 2024 |
Financial Forecast
Revenue This Year
3.64M
from 6.00M
Decreased by -39.37%
Revenue Next Year
6.83M
from 3.64M
Increased by 87.80%
EPS This Year
-1.09
from -0.79
EPS Next Year
-1.34
from -1.09
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 3.8M | 8.8M | 10.5M | |||
| Avg | 3.6M | 6.8M | 5.1M | |||
| Low | 3.5M | 4.1M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -37.0% | 142.4% | 53.6% | |||
| Avg | -39.4% | 87.8% | -25.4% | |||
| Low | -42.0% | 13.1% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.00 | -1.14 | -1.38 | |||
| Avg | -1.09 | -1.34 | -1.34 | |||
| Low | -1.11 | -1.65 | -1.28 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.